MX346239B - Composiciones y metodos de polipeptidos-complejo de quelato de oligonucleotido. - Google Patents

Composiciones y metodos de polipeptidos-complejo de quelato de oligonucleotido.

Info

Publication number
MX346239B
MX346239B MX2014014021A MX2014014021A MX346239B MX 346239 B MX346239 B MX 346239B MX 2014014021 A MX2014014021 A MX 2014014021A MX 2014014021 A MX2014014021 A MX 2014014021A MX 346239 B MX346239 B MX 346239B
Authority
MX
Mexico
Prior art keywords
methods
chelate complex
polypeptide compositions
oligonucleotide chelate
polypeptide
Prior art date
Application number
MX2014014021A
Other languages
English (en)
Spanish (es)
Other versions
MX2014014021A (es
Inventor
Andrew Vaillant
Michel Bazinet
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49581470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX346239(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of MX2014014021A publication Critical patent/MX2014014021A/es
Publication of MX346239B publication Critical patent/MX346239B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
MX2014014021A 2012-05-18 2013-05-17 Composiciones y metodos de polipeptidos-complejo de quelato de oligonucleotido. MX346239B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US201261695035P 2012-08-30 2012-08-30
PCT/CA2013/050379 WO2013170386A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods

Publications (2)

Publication Number Publication Date
MX2014014021A MX2014014021A (es) 2015-02-10
MX346239B true MX346239B (es) 2017-03-13

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014021A MX346239B (es) 2012-05-18 2013-05-17 Composiciones y metodos de polipeptidos-complejo de quelato de oligonucleotido.

Country Status (34)

Country Link
US (1) US9492506B2 (enExample)
EP (1) EP2849798B1 (enExample)
JP (1) JP2015517504A (enExample)
KR (1) KR102068109B1 (enExample)
CN (1) CN104349793B (enExample)
AU (1) AU2013262416B2 (enExample)
BR (1) BR112014028654A2 (enExample)
CA (1) CA2873529C (enExample)
CL (1) CL2014003134A1 (enExample)
CO (1) CO7131387A2 (enExample)
CR (1) CR20140527A (enExample)
CY (1) CY1124345T1 (enExample)
DK (1) DK2849798T3 (enExample)
DO (1) DOP2014000264A (enExample)
EA (1) EA035967B1 (enExample)
EC (1) ECSP14027694A (enExample)
ES (1) ES2873844T3 (enExample)
HR (1) HRP20210840T1 (enExample)
HU (1) HUE054875T2 (enExample)
IL (1) IL235548B (enExample)
LT (1) LT2849798T (enExample)
MX (1) MX346239B (enExample)
MY (1) MY168778A (enExample)
NZ (1) NZ703095A (enExample)
PH (1) PH12014502551B1 (enExample)
PL (1) PL2849798T3 (enExample)
PT (1) PT2849798T (enExample)
RS (1) RS62030B1 (enExample)
SG (1) SG11201407599SA (enExample)
SI (1) SI2849798T1 (enExample)
SM (1) SMT202100319T1 (enExample)
TW (1) TWI635864B (enExample)
WO (1) WO2013170386A1 (enExample)
ZA (1) ZA201408674B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943591B2 (en) 2007-05-11 2011-05-17 Adynxx, Inc. Gene expression and pain
PT2846839T (pt) 2012-05-10 2019-05-29 Adynxx Inc Formulações para a administração de ingredientes ativos
BR112015003985A2 (pt) * 2012-08-30 2017-08-08 Replicor Inc métodos para tratamento de infecções de hepatite b e hepatite d
JP2017521433A (ja) * 2014-07-10 2017-08-03 レプリコール インコーポレーティッド Ｂ型肝炎およびｄ型肝炎ウイルス感染の治療のための方法
AU2015301491A1 (en) 2014-08-15 2017-02-02 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
AU2019376079A1 (en) * 2018-11-08 2021-05-27 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2024255846A1 (en) * 2023-06-16 2024-12-19 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (ja) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ ミニマルｂ型肝炎感染症治療用医薬組成物
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
CN1694959B (zh) * 2002-09-13 2013-09-18 雷普利瑟公司 非序列互补的抗病毒寡核苷酸
EP1597278A4 (en) 2003-02-26 2006-03-22 Intermune Inc COMPOSITIONS OF POLYETHYLENE GLYCOL-MODIFIED INTERFERON AND METHOD FOR THE APPLICATION THEREOF
US20060003942A1 (en) * 2003-10-27 2006-01-05 Roger Tung Combinations for HCV treatment
JP2008516996A (ja) * 2004-10-19 2008-05-22 レプリコール インコーポレーティッド 抗ウイルス性オリゴヌクレオチド
WO2007022642A2 (en) 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
EP1942911A4 (en) * 2005-09-29 2009-08-19 Replicor Inc THERAPEUTIC MOLECULES AND USES THEREOF
WO2007041279A2 (en) * 2005-09-29 2007-04-12 S-Cell Biosciences, Inc. Methods to treat t-cell disorders using tisf
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
WO2009076679A2 (en) 2007-12-13 2009-06-18 Alnylam Pharmaceuticals Inc. Methods and compositions for prevention or treatment of rsv infection
CA2717792A1 (en) * 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
ES2618576T3 (es) * 2009-05-28 2017-06-21 Curna, Inc. Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico
EP2512491B1 (en) * 2009-10-16 2017-10-11 Glaxo Group Limited Hbv antisense inhibitors
HUE029521T2 (en) * 2010-08-20 2017-03-28 Replicor Inc Oligonucleotide chelate complexes
BR112015003985A2 (pt) 2012-08-30 2017-08-08 Replicor Inc métodos para tratamento de infecções de hepatite b e hepatite d

Also Published As

Publication number Publication date
EA035967B1 (ru) 2020-09-07
IL235548B (en) 2019-07-31
CY1124345T1 (el) 2022-07-22
ES2873844T3 (es) 2021-11-04
CA2873529A1 (en) 2013-11-21
KR20150013309A (ko) 2015-02-04
AU2013262416B2 (en) 2017-05-11
CL2014003134A1 (es) 2015-02-13
NZ703095A (en) 2016-07-29
AU2013262416A1 (en) 2014-12-18
DK2849798T3 (da) 2021-05-31
HRP20210840T1 (hr) 2021-08-06
PH12014502551B1 (en) 2019-10-11
CN104349793B (zh) 2017-11-10
EP2849798A1 (en) 2015-03-25
PL2849798T3 (pl) 2021-10-18
HK1204279A1 (en) 2015-11-13
PT2849798T (pt) 2021-05-18
BR112014028654A2 (pt) 2017-10-10
CA2873529C (en) 2020-08-18
PH12014502551A1 (en) 2015-01-21
TW201408308A (zh) 2014-03-01
EP2849798B1 (en) 2021-04-07
US9492506B2 (en) 2016-11-15
EA201401278A1 (ru) 2015-04-30
TWI635864B (zh) 2018-09-21
CO7131387A2 (es) 2014-12-01
SG11201407599SA (en) 2014-12-30
ZA201408674B (en) 2016-01-27
KR102068109B1 (ko) 2020-01-21
HUE054875T2 (hu) 2021-10-28
WO2013170386A1 (en) 2013-11-21
IL235548A0 (en) 2015-01-29
DOP2014000264A (es) 2015-01-31
MX2014014021A (es) 2015-02-10
US20130309201A1 (en) 2013-11-21
CN104349793A (zh) 2015-02-11
RS62030B1 (sr) 2021-07-30
SMT202100319T1 (it) 2021-09-14
SI2849798T1 (sl) 2021-08-31
ECSP14027694A (es) 2015-12-31
LT2849798T (lt) 2021-08-10
EP2849798A4 (en) 2016-03-09
JP2015517504A (ja) 2015-06-22
MY168778A (en) 2018-12-04
CR20140527A (es) 2014-12-15

Similar Documents

Publication Publication Date Title
PH12014502551A1 (en) Oligonucleotide chelate complex-polypeptide compositions and methods
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
IN2015DN01156A (enExample)
TN2015000278A1 (en) Autotaxin inhibitors
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
MY172292A (en) Vectors and sequences for the treatment of diseases
MX349004B (es) Nuevos compuestos.
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
MX2015011193A (es) Compuestos antivirales.
IN2014CN00572A (enExample)
MX2015011198A (es) Compuestos antivirales.
MY188071A (en) Pyridone derivatives for the treatment of viral infections and further diseases
MX2015010892A (es) Compuestos antivirales.
MX2015011125A (es) Compuestos antivirales.
IN2014DN10683A (enExample)
MX2015011126A (es) Compuestos antivirales.
CU20140133A7 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
GB201114923D0 (en) Immunogenic proteins and compositions
ZA201407866B (en) Composition for the prevention and treatment of viral infections caused by retroviruses

Legal Events

Date Code Title Description
FG Grant or registration